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Caspase-3ystem (UPS) includes 3 enzymes that conjugate ubiquitin to intracellular proteins
that are then recognized and degraded in the proteasome. The process participates in the regulation of cell
metabolism. In the kidney, the UPS regulates the turnover of transporters and signaling proteins and its
activity is down regulated in acidosis-induced proximal tubular cell hypertrophy. In chronic kidney disease
(CKD), muscle wasting occurs because complications of CKD including acidosis, insulin resistance,
inﬂammation, and increased angiotensin II levels stimulate the UPS to degrade muscle proteins. This
response also includes caspase-3 and calpains which act to cleave muscle proteins to provide substrates for
the UPS. For example, caspase-3 degrades actomyosin, leaving a 14 kDa fragment of actin in muscle. The
14 kDa actin fragment is increased in muscle of patient with kidney disease, burn injury and surgery. In
addition, acidosis, insulin resistance, inﬂammation and angiotensin II stimulate glucocorticoid production.
Glucocorticoids are also required for the muscle wasting that occurs in CKD. Thus, the UPS is involved in
regulating kidney function and participates in highly organized responses that degrade muscle protein in
response to loss of kidney function.
© 2008 Elsevier B.V. All rights reserved.All intracellular proteins and many extracellular proteins are
continually “turning over”, being degraded to their constituent
amino acids and replaced by synthesis of new proteins. Speciﬁc
nuclear or cytosolic proteins, including proteins in the endoplasmic
reticulum and mitochondria, are degraded at widely different rates;
these rates vary fromminutes for some regulatory enzymes, to days or
weeks for proteins like actin and myosin in skeletal muscle, to months
for hemoglobin in the red cell. Complex regulatory mechanisms
ensure that proteolytic and synthetic processes are highly selective
and precisely balanced because even a small decrease in synthesis or a
small acceleration of degradation, if sustained, will result in marked
loss of protein stores [36].
There are different proteolytic processes but in all tissues, the
majority of intracellular proteins are degraded by the ubiquitin–
proteasome system (UPS) [41]. However, extracellular proteins and
some cell surface proteins are engulfed by endocytosis and degraded
within lysosomes containing several acid-optimal proteases (e.g.,
cathepsins). Degradation of some cytosolic proteins in muscle is de-
graded in lysosomes [61]. In mammalian cells, there also are calcium-
activated, ATP-independent, cysteine proteases (calpains) and cas-
pases. The latter cytosolic proteases cleave proteins at aspartic acid
residues and are critical for the apoptotic process [43].1 713 798 5010.
l rights reserved.1. The ubiquitin–proteasome system
Initial steps in protein degradation by the UPS involve a series of 3
enzymes that link the cofactor, ubiquitin (Ub), onto proteins [26,36].
The enzymatic components that link chains of Ub onto proteins include
the E1 (Ub-activating enzyme) and E2 proteins (Ub-carrier or
conjugating proteins), which prepare Ub for conjugation. The third
enzyme, E3Ub-protein ligase, is a key factor in termsof the speciﬁcity of
proteolysis because speciﬁc E3 enzymes will recognize a speciﬁc
protein substrate. E3 enzymes catalyze the transfer of activated Ub to
the substrate until a chain of 4–5 Ub's are attached. The conjugation
reactions formUb-conjugated proteins which can be recognized by the
26S proteasome. The proteasome removes Ub and degrades the sub-
strate protein into small peptides [2]. In some cases, only a single
ubiquitin is conjugated to a substrate protein (i.e. monoubiqutination).
These substrate proteins are not degraded; instead, they are sorted into
endocytic compartments and the Golgi network for routing to the
plasma membrane or lysosomes [45]. The discovery of Ub and the
biochemistry of its conjugation to substrate proteins led to the 2004
Nobel Prize in Chemistry awarded to Avram Hershko, Aaron Ciechan-
over and IrwinRose (http://nobelprize.org/chemistry/laureates/2004/).
The initial step in the conjugation of Ub onto proteins is the
activation of Ub at its carboxy-terminus by the E1, Ub-activating
enzyme. A single E1 enzymeuses ATP to generate aUb thiolesterwhich
is subsequently transferred to a sulfhydryl group of one of 30–40 E2
carrier proteins [20]. The major determinant of the speciﬁcity of the
Ub-conjugating process, however, is the presence of more than a
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it. For example, in muscle wasting conditions, two E3 Ub-conjugating
enzymes, Atrogin-1 (also known asMAFbx) andMuRF-1, are critical for
the breakdown of muscle proteins [3]. In cultured muscle cells, the
content of Atrogin-1 mRNA correlates closely with rates of protein
breakdown [42,44,49]. In models of muscle wasting conditions, their
expression increases dramatically (8–20 fold) and this increased
expression of Atrogin-1 and MuRF-1 occurs just when muscle atrophy
ismost rapid. Thus, themuscle content of these E3mRNAsmight prove
useful as biomarkers of excessive proteolysis in muscle. The signals
that activate these E3 Ub-conjugating enzymes have been extensively
studied and at least two transcription factors regulating E3 enzyme
expression have been identiﬁed. Forkhead transcription factors (FoxO)
and the inﬂammatory transcription factor, NFκB, act on the promoters
for Atrogin-1 and MuRF-1 respectively to stimulate their expression.
Moreover, it has been shown that activation of FoxO or NFκB causes
accelerated muscle wasting presumably via these E3s in conjunction
with other atrogenes [6,28,44].
In the kidney and other organs, at least ﬁve major functions of
the UPS can be identiﬁed: 1) the UPS permits cells to adapt to
changes in physiological functions by rapidly removing proteins to
terminate an enzymatic or regulatory process. 2) The UPS can change
gene expression by degrading transcription factors or cofactors/
inhibitors that regulate transcription. An example of this process is
the phosphorylation that initiates IκB degradation, releasing the
transcriptional activator NFκB. This factor acts to accelerate inﬂam-
matory responses. 3) The UPS eliminates abnormally folded or
damaged proteins. Patients with cystic ﬁbrosis have a mutant trans-
membrane conductance regulator protein (CFTR) which is selectively
degraded and hence, does not reach the cell surface. The result is
inadequate removal of secreted proteins, congesting a patient's
airways [19]. 4) The UPS functions to present antigen on the major
histocompatibility complex class I molecules [41]. 5) Finally, the UPS
degrades cellular proteins (including muscle proteins) when calories
are inadequate or in response to catabolic illnesses. These reactions
provide amino acids that are used for gluconeogenesis and the
synthesis of new proteins.
2. Protein metabolism and the UPS in the kidney
In the kidney, the UPS plays a critical role in the turnover of
proteins that affect cellular function, including the regulation of ion
channels. Malik et al., found that the UPS played a key role in
regulating the turnover of the amiloride-sensitive epithelial sodium
channel (ENac) in renal cells [29,30]. The physiologic relevance of
changing sodium channel activity was demonstrated by inhibiting the
UPS which led to greater activity of ENac, a condition reminiscent of
Liddle's syndrome, characterized by hypertension. Evidence that the
UPS is involved in functions of the kidney by regulating transcriptional
responses was found in studies of hypoxia-inducible factor 1 or HIF-1
[17]. It was determined that blocking the UPS changes expression of
HIF-1 and hence affects the kidney response to low oxygen supply.
Another example of how the UPS affects the regulation of kidney cell
functionwas found in studies of the responses to TGF-β. It was shown
that Smurf-2 (Smad ubiquitination regulatory factor-2), an E3
ubiquitin ligase was up regulated in the kidney tubule cells of patients
with obstructive kidney disease [50]. Smurf-2 can suppress Smad
transcriptional corepressors, SnoN and Ski thereby altering TGF-β
signaling transmission to promote ﬁbrosis in the kidney.
The UPS is also critically involved in regulating the bulk of proteins
in kidney cells in conditions associated with an increase in kidney cell
mass. In response to accumulation of excess acid, proximal tubule
epithelial cell hypertrophy increases glutamine/glutamate metabo-
lism to promote ammonia formation and the excretion of acid. The
hypertrophic response involves a decrease in protein degradation
along with a minor increase in protein synthesis [21]. Franch et al.,examinedmechanisms underlying the increase in proximal tubule cell
mass by studying the response to EGF as a signal for cell hypertrophy
[13]. EGF stimulated two hypertrophic responses, an increase in
protein synthesis and suppression of protein breakdown. The
mechanism involved both the UPS and lysosomes. The mechanisms
underlying the hypertrophy of kidney cells in response to diabetes or
unilateral nephrectomy have not been established.
3. Maintenance of protein stores in chronic kidney disease
Based on epidemiologic studies, chronic kidney disease afﬂicts
millions of adults in the U.S. and the world and sharply increases their
risk of cardiovascular disease [9]. In addition, CKD is associated with
muscle wasting and loss of protein stores, conditions associated with
excessive morbidity [25]. The loss of protein stores in CKD has been
attributed to “malnutrition” (i.e., abnormalities caused by an insufﬁ-
cient or imbalanced diet). This is incorrect because changing the diet
generally does not correct these abnormalities because they are due to
complex metabolic adaptation [34]. With progressive loss of kidney
function, the overall rates of muscle protein synthesis may decrease,
but the more prominent response is an increase in rates of protein
degradation [1,14–16,33,40]. Because protein turnover in humans is
very high (3.5–4.5 g protein/kg/day) [36], even a small, persistent
increase in proteolysis will cause marked protein depletion. Pro-
grammed activation of the UPS accounts for most of the accelerated
muscle protein degradation CKD.
4. Mechanisms causing loss of muscle protein in CKD
Recent studies in rodent models of CKD have established that the
accelerated muscle wasting induced by uremia involves cellular
mechanisms that are similar to the mechanisms causing muscle
wasting in other catabolic conditions, such as cancer cachexia, star-
vation, insulin deﬁciency/resistance, or sepsis [26,36]. The mechanism
of muscle wasting in these catabolic states involves accelerated
proteolysis via the UPS plus higher levels of mRNAs encoding certain
components of the UPS. There are also changes (both increases and
decreases) in the expression of about 100 atrophy-related genes called
atrogenes [27]. The increase in muscle mRNA levels of atrophy-related
genes in muscle wasting states occurs because of increased gene
transcription [1,27,35,38]. In fact, there is a common transcriptional
program that includes decreased expression of various growth-related
genes in atrophying muscle leading to the conclusion that multiple
transcriptional factors change coordinately, resulting in loss of muscle
mass [27]. The strongest evidence for activation of the UPS in muscles
of animals undergoing atrophy due to uremia (or other catabolic
diseases) is that inhibitors of the proteasome provided in vitro will
block the increase in protein degradation present in muscles isolated
from rodents with various models of catabolic human diseases
[1,38,51]. In humans as well, catabolic conditions stimulate activation
of the UPS in muscle (i.e., an increase in mRNAs encoding Ub and
proteasome subunits) [31,37,53,58].
Loss of kidney function is associated with many abnormalities,
some of which have been identiﬁed as signals stimulating protein
degradation inmuscle. For example, the accumulation of acid from the
reduced capacity to excrete acid stimulates protein degradation in
muscle [33]. Secondly, insulin resistance can be present in CKD pa-
tients with only moderate renal insufﬁciency and it stimulates protein
degradation in muscle [24,28,35,38,56].
Another common problem for CKD patients is hypertension and
cardiovascular disease linked to an increase in angiotensin II levels.
This response, like those related to acidosis or insulin resistance, causes
muscle atrophy in rodents [5,47]. Finally, CKD patients frequently have
high levels of inﬂammatory cytokines, raising the possibility that
muscle protein degradation is accelerated because of inﬂammation
[6,23].
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Muscle atrophy in catabolic conditions speciﬁcally affects contrac-
tile proteins [8]. Since myoﬁbrillar proteins comprise about 2/3 of the
protein in muscle, loss of these proteins is largely responsible for the
disability of patients who experience muscle wasting. Notably,
degradation of myoﬁbrillar proteins requires more than one proteo-
lytic step because the UPS can readily degrade major components of
themyoﬁbril (actin, myosin, troponin or tropomyosin) but when these
same proteins are present in complexes or in intactmyoﬁbrils, they are
degraded very slowly by the UPS [46]. Therefore, other proteases must
initially cleave proteins to break down the complex structure ofmuscle
to produce substrates for the UPS. In exploring proteases that could
initiate cleavage of myoﬁbrillar proteins, we examined caspases be-
cause several catabolic states are characterized by high circulating
levels of TNFα and insulin resistance, conditions that activate the
caspase cascade [11,18,23]. We found that activated caspase-3 cleaves
actomyosin in vitro and when stimulated in cultured muscle cells,
there is cleavage of myoﬁbrillar proteins that are rapidly degraded by
the UPS.
Notably, caspase-3 activation produces a “footprint” of its activity, a
14 kDa C-terminal fragment of actin that is found in the insoluble
fraction of muscle [12]. Localization of the fragment to the insoluble
fractionpresumably occurs because it is less susceptible to degradation
by the UPS. We ﬁnd accumulation of the 14 kDa actin fragment in
muscles of animals with accelerated protein degradation due to
acidosis, diabetes, and angiotensin II-induced hypertension, all
complications of CKD [12,28,56,56] (Fig. 1). In patients with CKD or
other causes of muscle wasting as well, we ﬁnd that the level of the
14 kDa actin fragment is increased in muscle. In addition, the level of
the 14 kDa actin fragment in muscle of CKD patients decreases in
response to an exercise program directed at increasing the patient's
endurance. In addition, we found that the level of the fragment was
highly correlated (r=0.78) with the measured rate of protein degrada-
tion in muscles of patients with muscle wasting from osteoarthritis.
Finally, the 14 kDa actin fragment in unburnedmuscle of patients who
had suffered a major burn injury was sharply increased [60]. These
results indicate that at least in these conditions, the level of the 14 kDa
fragment in muscle is closely related to the rate of protein degradation
and is present in speciﬁc disorders characterized by muscle wasting
[1,7]. Additional testing will be needed to determine if this method
could serve as a biomarker of accelerated muscle protein degradation
in other conditions causing muscle wasting.Fig. 1. Complications of CKD including increased levels of angiotensin II, the presence of
inﬂammation, insulin resistance and/or acidosis, impair insulin/IGF-1 signaling. The
impairment decreases Akt phosphorylation, resulting in an increase in caspase-3
activity which disrupts the complex structure of muscle proteins and creates substrates
for the UPS. The UPS activity is stimulated by Forkhead transcription factor (FoxO)
which promotes expression of atrogenes including components of the UPS. The result is
stimulation of muscle protein degradation.Another family of proteases, the calpains, has also been suggested
as the protease that initially cleaves myoﬁbrillar proteins in conditions
associated with muscle wasting. Calpains are calcium-dependent,
cysteine proteases that could play a role in disorders that include
muscular dystrophy or sepsis-inducedmusclewasting [54,57]. At least
in rodents with uremia or certain other types of atrophy the inhibition
of calcium-activated proteases inmuscle does not block the increase in
protein degradation, the degradation of myoﬁbrillar proteins, or the
accumulation of the 14 kDa actin fragment in muscle cells [1,12].
Additional studies are needed to (a) determine whether different
catabolic disorders stimulate caspase-3 and/or calpains and (b) explain
the speciﬁc roles of these proteases in the breakdown of different
muscle proteins.
6. Signals triggeringmuscle wasting in CKD or other catabolic states
CKD is associated with several complications that can trigger the
UPS to degrade muscle protein. These include metabolic acidosis,
decreased insulin action and angiotensin II levels, and/or inﬂammation
[1,38,47,48]. There is evidence that these complications can function in
concert to cause muscle wasting. For example, metabolic acidosis
stimulates protein breakdown by the UPS in muscle by integrating
abnormalities, including an increase in glucocorticoid production and
the development of insulin resistance in muscle [28,32]. Notably,
however, acidiﬁcation alone does not stimulate muscle protein break-
down unless a physiological amount of glucocorticoids is also present
[32,39]. Likewise, glucocorticoids are required to for the accelerated
protein degradation documented to occur in models of diabetes, high
levels of angiotensin II, and sepsis [35,47,52].
Inﬂammatory conditions are frequently present in CKD patients
but it is not clear how they affect muscle protein degradation [22]. One
possibility is that Inﬂammation suppresses insulin signaling and in-
creases glucocorticoid production. These responses could explainwhy
there is a requirement for glucocorticoids in the accelerated muscle
protein degradation that occurs in response to sepsis [52].
Thirdly, decreased insulin/IGF-1 signaling could be the stimulus for
acceleratedmuscle protein breakdown. One consequence of decreased
insulin signaling would be a decrease in protein synthesis. Themecha-
nism would involve decreased signaling through the phosphatidyli-
nositol 3-kinase/Akt (PI3K/Akt) pathway [4,28]. Speciﬁcally, when
insulin or IGF-1 signaling is low, PI3K activity falls, reducing the
production of phosphadidylinositol-3,4,5 phosphate, the active pro-
duct of PI3K. This results in a decrease in the phosphorylation and
activity of the serine/threonine kinase, Akt. With a decrease in Akt
activation, there would be decreased phosphorylation of downstream
kinases, GSK1 and mTOR/S6kinase, suppressing protein synthesis.
Similarly, decreased PI3K/Akt signaling is the key step in stimulating
protein degradation in muscle. Decreased PI3K/Akt signaling will
induce the expression of the E3's Ub-conjugating enzymes, Atrogin-1
and MuRF-1, enhancing muscle protein degradation [28,44,49].
Expression of these E3 enzymes occurs because there is decreased
phosphorylation of the forkhead family of transcription factors (FoxO1,
3, 4). When FoxO1, 3 and 4 are not phosphorylated, they can migrate
into the nucleus to stimulate transcription of Atrogin-1 [28,44,49].
Insulin or IGF-1 can block this process by stimulating activity of the
PI3K/Akt pathway to suppress the expression of Atrogin-1.
Besides stimulating the expression of speciﬁc E3 Ub ligases, the
insulin/IGF-1-PI3K/Akt pathway regulates the activation of caspase-3
to initiate the breakdown of muscle proteins. For example, in insulin-
deﬁcient rats with accelerated muscle protein degradation, we found
activation of the pro-apoptotic factor, Bax. This leads to the release of
cytochrome C frommitochondria and activation of caspase-3 [28]. The
result is increased production of the 14 kDa actin fragment. This
pathway was conﬁrmed in cultured muscle cells with inhibited PI3K
activity using genetic or pharmacological techniques. Together, these
results provide evidence that muscle wasting in response to the
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alters key enzymes modulating protein synthesis and degradation.
A key endocrine factor that participates in the regulation of muscle
protein turnover is glucocorticoids. Pharmacologic doses of glucocor-
ticoids have been used as a mechanism to activate the UPS to degrade
muscle proteins and to study the activation of Atrogin-1 [10,42,55].
However, the response to pharmacologic doses of glucocorticoids
differs from the physiologic responses. In vivo, catabolic conditions do
not stimulate muscle wasting unless a physiologic level of glucocorti-
coids is present. Evidence for this difference in the responses is
present in studies of adrenalectomized rodents: when they were
starved or treated with NH4Cl to induce metabolic acidosis or made
insulin-deﬁcient with streptozotocin, muscle protein degradation did
not increase unless the animals are also given a physiological dose of
glucocorticoids [35,39,59]. Similarly, the increase in muscle wasting
induced by angiotensin II or sepsis can be blocked by inhibiting the
glucocorticoid receptor [47]. Thus, glucocorticoids exert a permissive
role because the same dose of glucocorticoids does not stimulate
muscle wasting in adrenalectomized animals. These results as well as
the analysis of the complex transcriptional responses that are present
in catabolic conditions indicate that muscle wasting results from
activation of a regulated pathway that is of protein degradation that is
integrated with changes in protein synthesis.
In this brief review of the UPS in kidney disease, we have
emphasized that activity of the UPS in kidney cells is important for
controlling levels of regulatory proteins. The UPS also participates in
the turnover of the bulk of proteins in kidney epithelial cells. The
responses of kidney and muscle cells to certain conditions such as
acidosis, however, occur in opposite directions, and it is not clear how
such opposing responses are regulated. Finally, speciﬁc complications
of kidney disease have been shown to coordinate the activity of
proteolytic systems (i.e., caspase-3 and the UPS) to degrade muscle
proteins. These responses appear to apply to other catabolic condi-
tions associated with muscle wasting and involve defects in insulin/
IGF-1 signaling pathways and decreased PI3K/Akt signaling. Under-
standing these regulatory mechanisms could blunt the muscle
wasting that occurs in different catabolic conditions.
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